Antimicrobial Agents — MCQs

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 491: Which of the following drug combinations is NOT considered favourable?

A. Amoxicillin and clavulanic acid
B. Ampicillin and cloxacillin (Correct Answer)
C. Piperacillin and tazobactam
D. Ampicillin and tazobactam

Explanation: ### Explanation The core concept behind these combinations is the use of **Beta-lactamase inhibitors** to protect Beta-lactam antibiotics from enzymatic degradation. **1. Why Ampicillin and Cloxacillin is NOT favorable:** This combination is considered **irrational** and redundant. Ampicillin is a broad-spectrum penicillin sensitive to penicillinase, while Cloxacillin is a penicillinase-resistant (antistaphylococcal) penicillin. * **Lack of Synergy:** Cloxacillin does not inhibit the beta-lactamase enzymes that destroy Ampicillin; it simply resists them itself. * **Spectrum Overlap:** They do not broaden the spectrum effectively against Gram-negative bacteria. * **Clinical Practice:** Using them together offers no therapeutic advantage over using a single appropriate agent and increases the risk of adverse effects [1]. **2. Analysis of Incorrect Options (Favorable Combinations):** Options A, C, and D are all examples of a **Beta-lactam antibiotic + Beta-lactamase inhibitor (BLI)**. The BLI (Clavulanic acid, Tazobactam) has no significant antibacterial activity of its own but binds irreversibly to beta-lactamase enzymes ("suicide inhibition"), preventing the destruction of the parent antibiotic. * **Amoxicillin + Clavulanic acid:** Standard for community-acquired infections. * **Piperacillin + Tazobactam:** A potent combination for hospital-acquired infections (including *Pseudomonas*). * **Ampicillin + Sulbactam/Tazobactam:** Effective against many Gram-positive and Gram-negative anaerobes. **High-Yield Clinical Pearls for NEET-PG:** * **Suicide Inhibitors:** Clavulanic acid, Sulbactam, and Tazobactam are called suicide inhibitors because they are inactivated after binding to the enzyme. * **Newer BLIs:** Avibactam and Relebactam are non-beta-lactam beta-lactamase inhibitors used against multi-drug resistant Gram-negative bacteria. * **Fixed-Dose Combinations (FDCs):** The WHO and Indian regulatory bodies have flagged Ampicillin + Cloxacillin as an irrational FDC that contributes to antibiotic resistance.

Question 492: Macrocytic anemia is caused by all EXCEPT:

A. Pyrimethamine
B. Methotrexate
C. Pentamidine (Correct Answer)
D. Trimethoprim

Explanation: **Explanation:** The core concept behind this question is the inhibition of **Dihydrofolate Reductase (DHFR)**, an enzyme essential for converting dihydrofolate into tetrahydrofolate. Tetrahydrofolate is a critical cofactor for DNA synthesis; its deficiency leads to impaired nuclear maturation while the cytoplasm continues to grow, resulting in **megaloblastic (macrocytic) anemia**. **Why Pentamidine is the Correct Answer:** Pentamidine is an antiprotozoal agent used primarily for *Pneumocystis jirovecii* and Leishmaniasis. Its mechanism involves interfering with oxidative phosphorylation and DNA synthesis by binding to the minor groove of DNA. Crucially, **Pentamidine does not inhibit the folate pathway** or DHFR. Therefore, it does not cause macrocytic anemia. Its primary toxicities include nephrotoxicity, hypoglycemia/diabetes, and hypotension. **Analysis of Incorrect Options:** * **Pyrimethamine:** An antiprotozoal (used in Toxoplasmosis) that selectively inhibits protozoal DHFR. At high doses, it can cross-react with human DHFR, leading to folate deficiency. * **Methotrexate:** A potent inhibitor of human DHFR used in chemotherapy and autoimmune diseases. It is a classic cause of drug-induced megaloblastic anemia. * **Trimethoprim:** An antibacterial that inhibits bacterial DHFR. Similar to pyrimethamine, prolonged or high-dose use can affect human DHFR, especially in patients with borderline folate stores. **High-Yield Clinical Pearls for NEET-PG:** * **Rescue Therapy:** To prevent macrocytic anemia caused by DHFR inhibitors (like Methotrexate), **Leucovorin (Folinic acid)** is administered. It bypasses the blocked DHFR enzyme. * **Other Drugs causing Macrocytosis:** Phenytoin (interferes with absorption), Zidovudine (AZT), and Hydroxyurea. * **Mnemonic:** Drugs acting on DHFR = **"M-P-T"** (Methotrexate, Pyrimethamine, Trimethoprim).

Question 493: Basiliximab acts by antagonism against which receptor?

A. CD 25 (Correct Answer)
B. CD 11a
C. TNF
D. All of the above

Explanation: **Explanation:** **Basiliximab** is a chimeric monoclonal antibody used primarily as an induction agent in organ transplantation to prevent acute rejection. 1. **Why CD 25 is correct:** Basiliximab acts as a competitive antagonist to the **CD 25** receptor. CD 25 is the **alpha subunit of the Interleukin-2 (IL-2) receptor**, which is specifically expressed on the surface of activated T-lymphocytes. By binding to CD 25, Basiliximab prevents IL-2 from binding to its receptor, thereby inhibiting T-cell proliferation and activation—the key drivers of graft rejection. 2. **Why other options are incorrect:** * **CD 11a:** This is a component of LFA-1 (Lymphocyte Function-associated Antigen-1). **Efalizumab** (now withdrawn) was the monoclonal antibody targeting CD 11a. * **TNF (Tumor Necrosis Factor):** Drugs targeting TNF-alpha include **Infliximab, Adalimumab, and Etanercept**. These are used in autoimmune conditions like Rheumatoid Arthritis and Crohn’s disease, not as primary induction agents in transplant surgery. **High-Yield Clinical Pearls for NEET-PG:** * **Daclizumab** is another monoclonal antibody that targets CD 25 (though it was primarily used for Multiple Sclerosis before being withdrawn). * **Selectivity:** Unlike older immunosuppressants (like Cyclosporine), Basiliximab is highly selective because CD 25 is only expressed on *activated* T-cells, not resting ones. * **Adverse Effects:** It is generally well-tolerated; however, clinicians must monitor for hypersensitivity reactions and increased risk of opportunistic infections. * **Mnemonic:** "Basi-**LI**-ximab" targets the **I**nter-**L**eukin (IL-2) receptor.

Question 494: All of the following are common antimicrobial agents used in the treatment of typhoid fever except?

A. Ceftriaxone
B. Quinolones
C. Clindamycin (Correct Answer)
D. Azithromycin

Explanation: **Explanation:** Typhoid fever (Enteric fever) is caused by *Salmonella typhi* and *Salmonella paratyphi*, which are **Gram-negative bacilli**. The treatment strategy focuses on agents that achieve high intracellular concentrations and are effective against Gram-negative organisms. **Why Clindamycin is the correct answer:** Clindamycin is a lincosamide antibiotic primarily effective against **Gram-positive cocci** (like MRSA) and **anaerobes**. It has no significant activity against Gram-negative aerobic bacilli like *Salmonella*. Therefore, it has no role in the management of typhoid fever. **Analysis of other options:** * **Ceftriaxone (Option A):** Currently the **drug of choice** for empirical treatment of typhoid fever, especially in areas with high rates of multi-drug resistance (MDR). It is a third-generation cephalosporin with excellent Gram-negative coverage. * **Quinolones (Option B):** Drugs like Ciprofloxacin were historically the first-line treatment. However, due to rising "decreased susceptibility to ciprofloxacin" (DSC), they are now reserved for sensitive strains. * **Azithromycin (Option C):** An oral macrolide used as a first-line agent for uncomplicated typhoid, particularly in cases of fluoroquinolone resistance. It achieves high intracellular concentrations, making it effective against the intracellular *Salmonella*. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (Empirical):** Ceftriaxone. * **Drug of Choice (Sensitive strains):** Fluoroquinolones (e.g., Ciprofloxacin). * **Carrier State Treatment:** Cholecystectomy + Ampicillin or Norfloxacin (for 4–6 weeks). * **MDR Typhoid:** Defined as resistance to Chloramphenicol, Ampicillin, and Cotrimoxazole.

Question 495: Which of the following drugs is most likely to cause myelosuppression?

A. Famciclovir
B. Ganciclovir (Correct Answer)
C. Penciclovir
D. Fomivirsen

Explanation: Explanation: The correct answer is Ganciclovir. 1. Why Ganciclovir is correct: Ganciclovir is a potent antiviral used primarily for Cytomegalovirus (CMV) infections [3]. Unlike Acyclovir, Ganciclovir has a much higher affinity for host cellular DNA polymerases. When it is phosphorylated to its active triphosphate form, it can be incorporated into the DNA of rapidly dividing human cells, particularly in the bone marrow. This leads to its most significant dose-limiting toxicity: Myelosuppression (specifically neutropenia in ~15-40% of patients and thrombocytopenia) [1]. 2. Why the other options are incorrect: * Famciclovir & Penciclovir: These are used primarily for HSV and VZV [2]. They have a much higher selectivity for viral thymidine kinase over host enzymes compared to Ganciclovir. Consequently, they are well-tolerated and rarely cause significant hematological toxicity [5]. * Fomivirsen: This is an antisense oligonucleotide used (historically) for CMV retinitis via intravitreal injection. Because it is administered locally and works by binding to viral mRNA rather than inhibiting DNA polymerase, it does not cause systemic myelosuppression. 3. NEET-PG High-Yield Pearls: * Dose-limiting toxicity: For Ganciclovir, it is bone marrow suppression [1]; for Foscarnet (another anti-CMV drug), it is nephrotoxicity and electrolyte imbalances [4]. * Drug Interaction: Avoid co-administering Ganciclovir with Zidovudine (AZT), as both cause myelosuppression, leading to additive hematologic toxicity [1]. * Valganciclovir: The oral prodrug of Ganciclovir; it shares the same toxicity profile [1], [2]. * Treatment of Toxicity: G-CSF (Filgrastim) can be used to manage Ganciclovir-induced neutropenia.

Question 496: In an asymptomatic patient, which of the following biochemical profiles necessitates the discontinuation of Isoniazid (INH)?

A. Alanine aminotransferase (ALT) levels greater than 5 times the upper limit of normal (Correct Answer)
B. ALT level greater than 3 times the upper limit of normal
C. ALT levels greater than 2 times the upper limit of normal
D. ALT levels greater than 10 times the upper limit of normal

Explanation: ### Explanation The management of Isoniazid (INH) induced hepatotoxicity is a high-yield topic in NEET-PG. The decision to discontinue therapy is based on the presence or absence of symptoms and the degree of elevation in serum transaminases (ALT/AST). **Why Option A is correct:** According to standard guidelines (ATS/CDC), in an **asymptomatic** patient, INH should be discontinued if the ALT/AST levels exceed **5 times the upper limit of normal (ULN)**. This threshold is set because mild elevations (up to 3 times ULN) are common and often transient (adaptive) during the first few weeks of therapy. However, a 5-fold increase indicates a significant risk of progressing to severe hepatic necrosis. **Analysis of Incorrect Options:** * **Option B:** ALT >3 times ULN is the threshold for discontinuation **only if the patient is symptomatic** (e.g., nausea, vomiting, abdominal pain, or jaundice). In asymptomatic patients, this level requires close monitoring but not immediate cessation. * **Option C:** ALT >2 times ULN is considered a mild elevation and is frequently observed in up to 20% of patients starting anti-tubercular treatment (ATT). It does not warrant discontinuation. * **Option D:** ALT >10 times ULN is a dangerously high level. While discontinuation is mandatory here, the clinical "cutoff" or "trigger" point for safety is much lower (at 5 times ULN). **Clinical Pearls for NEET-PG:** * **Mechanism:** INH hepatotoxicity is mediated by its metabolite, **Acetylhydrazine**. * **Risk Factor:** **Slow acetylators** are at a higher risk of peripheral neuropathy, while the relationship between acetylation status and hepatotoxicity is more complex (though often associated with fast acetylators in some studies, current consensus focuses on the accumulation of toxic metabolites). * **Reintroduction:** Once enzymes return to <2 times ULN, drugs are reintroduced one by one, starting with Rifampicin, then Isoniazid, and finally Pyrazinamide. * **Most Hepatotoxic ATT:** Pyrazinamide > Isoniazid > Rifampicin. (Note: Ethambutol and Streptomycin are non-hepatotoxic).

Question 497: All of the following are side effects of Quinine except:

A. QT prolongation
B. Tinnitus
C. Teratogenicity (Correct Answer)
D. Hypoglycemia

Explanation: Explanation: The correct answer is **C. Teratogenicity**. Quinine, a cinchona alkaloid used primarily for chloroquine-resistant malaria, is **not considered teratogenic** at therapeutic doses. In fact, it is the drug of choice for treating uncomplicated malaria during the **first trimester of pregnancy** (according to WHO guidelines), as the benefits of treating life-threatening malaria far outweigh the potential risks. **Analysis of Incorrect Options:** * **QT Prolongation (Option A):** Quinine has "quinidine-like" effects on the heart. It blocks myocardial potassium channels, leading to a prolonged QT interval and an increased risk of polymorphic ventricular tachycardia (Torsades de Pointes) [2]. * **Tinnitus (Option B):** This is a hallmark symptom of **Cinchonism**, a dose-dependent toxicity syndrome. It presents with tinnitus, high-frequency hearing loss, dizziness, headache, and blurred vision [1], [2]. * **Hypoglycemia (Option D):** Quinine is a potent stimulator of pancreatic beta cells, leading to hyperinsulinemia. This is a common and serious side effect, especially in pregnant women and patients with severe malaria. **High-Yield Clinical Pearls for NEET-PG:** 1. **Cinchonism:** The classic triad includes tinnitus, visual disturbances, and headache [1]. 2. **Blackwater Fever:** A rare but severe reaction to Quinine characterized by massive intravascular hemolysis, hemoglobinuria, and acute renal failure. 3. **Drug of Choice:** While Quinine is used in the first trimester, **Artesunate (IV)** is the preferred drug for *severe* malaria across all trimesters. 4. **G6PD Deficiency:** Quinine can trigger hemolysis in G6PD-deficient individuals, though it is less common than with Primaquine.

Question 498: Which one of the following drugs is an antipseudomonal penicillin?

A. Cephalexin
B. Cloxacillin
C. Piperacillin (Correct Answer)
D. Dicloxacillin

Explanation: **Explanation:** **Correct Option: C. Piperacillin** Piperacillin is an **extended-spectrum penicillin** belonging to the ureidopenicillin class. It is specifically designed to penetrate the outer membrane of Gram-negative bacteria, including *Pseudomonas aeruginosa*. It is often combined with the beta-lactamase inhibitor **tazobactam** (Zosyn) to broaden its spectrum against beta-lactamase-producing organisms. **Incorrect Options:** * **A. Cephalexin:** This is a **1st-generation cephalosporin**. While effective against Gram-positive cocci and some enteric Gram-negatives (PEK: *Proteus, E. coli, Klebsiella*), it has **no activity** against *Pseudomonas*. * **B. Cloxacillin & D. Dicloxacillin:** These are **Penicillinase-resistant penicillins** (Antistaphylococcal penicillins). Their bulky side chains protect the beta-lactam ring from staphylococcal beta-lactamase. They are the drugs of choice for MSSA (*Methicillin-sensitive Staphylococcus aureus*) but lack activity against Gram-negative bacteria like *Pseudomonas*. **High-Yield Clinical Pearls for NEET-PG:** 1. **Antipseudomonal Penicillins:** Divided into Carboxypenicillins (Ticarcillin, Carbenicillin) and Ureidopenicillins (Piperacillin, Mezlocillin). **Piperacillin** is the most potent of this group. 2. **Other Antipseudomonal Beta-lactams:** * **Cephalosporins:** Ceftazidime (3rd gen), Cefepime (4th gen), and Cefoperazone. * **Carbapenems:** Imipenem, Meropenem, and Doripenem (**Note:** Ertapenem does *not* cover *Pseudomonas*). * **Monobactams:** Aztreonam (safe in penicillin-allergic patients). 3. **Synergy:** Antipseudomonal penicillins are frequently combined with **Aminoglycosides** (like Amikacin) for synergistic effects and to prevent the development of resistance.

Question 499: Which of the following is NOT useful in the management of Clostridium difficile colitis?

A. Clindamycin (Correct Answer)
B. Metronidazole
C. Fidaxomycin
D. Fecal microbiota transplantation

Explanation: **Explanation:** The correct answer is **Clindamycin (Option A)**. **1. Why Clindamycin is the correct answer:** Clindamycin is not a treatment for *Clostridium difficile* infection (CDI); rather, it is one of the most notorious **inciting agents** that cause it. Clindamycin suppresses the normal protective anaerobic flora of the gut, allowing *C. difficile* to overgrow and release toxins (Toxin A and B). While almost any antibiotic can cause CDI, Clindamycin, Fluoroquinolones, and Cephalosporins carry the highest risk. **2. Why the other options are incorrect:** * **Metronidazole (Option B):** Historically the first-line drug for mild-to-moderate CDI [2]. While recent guidelines (IDSA) favor Vancomycin, Metronidazole remains an alternative in resource-limited settings or for non-severe cases [2]. * **Fidaxomicin (Option C):** A macrocyclic antibiotic that inhibits RNA polymerase [1]. It is highly selective for *C. difficile* with minimal effect on normal gut flora, leading to lower recurrence rates. It is now considered a first-line treatment alongside oral Vancomycin. * **Fecal Microbiota Transplantation (Option D):** This involves transferring stool from a healthy donor to restore gut microbiome diversity. It is highly effective and recommended for patients with multiple recurrences of CDI. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (Initial Episode):** Oral Vancomycin or Fidaxomicin. * **Mechanism of Fidaxomicin:** Inhibition of RNA polymerase (Sigma subunit). * **Bezlotoxumab:** A monoclonal antibody against *C. difficile* Toxin B, used to prevent recurrence. * **Diagnosis:** Confirmed by detecting *C. difficile* toxins in stool (EIA) or GDH antigen.

Question 500: Enzyme inactivation is the main mode of resistance to which class of antimicrobial agents?

A. Aminoglycosides (Correct Answer)
B. Quinolones
C. Rifampicin
D. Glycopeptides

Explanation: **Explanation:** The primary and most common mechanism of resistance to **Aminoglycosides** is **enzymatic inactivation** by bacterial enzymes. Bacteria produce aminoglycoside-modifying enzymes (AMEs) such as acetyltransferases, nucleotidyltransferases, and phosphotransferases. These enzymes modify the hydroxyl or amino groups of the drug molecule, preventing it from binding to the 30S ribosomal subunit, thereby rendering the antibiotic ineffective. **Analysis of Incorrect Options:** * **Quinolones (e.g., Ciprofloxacin):** Resistance primarily occurs through **target site mutation** (mutations in DNA gyrase or Topoisomerase IV) and decreased permeability via porin loss or efflux pumps. * **Rifampicin:** Resistance is almost exclusively due to a **mutation in the *rpoB* gene**, which alters the target site (the beta-subunit of bacterial DNA-dependent RNA polymerase). * **Glycopeptides (e.g., Vancomycin):** Resistance (seen in VRE) occurs through **target site modification**, where the D-Ala-D-Ala terminus of the peptidoglycan precursor is changed to D-Ala-D-Lac, reducing drug affinity. **High-Yield Clinical Pearls for NEET-PG:** * **Aminoglycosides:** While enzymatic inactivation is the *most common* mechanism, they can also face resistance via decreased uptake (anaerobes are innately resistant because uptake requires an oxygen-dependent transport system). * **Amikacin** is the aminoglycoside most resistant to these bacterial enzymes, making it effective against many organisms resistant to Gentamicin or Tobramycin. * **Beta-lactams:** Also frequently use enzyme inactivation (Beta-lactamases) as a major resistance mechanism, but among the options provided, Aminoglycosides is the classic example.

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free